Antineoplastic Agents, Hormonal
"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Hormonal
- Hormonal Agents, Antineoplastic
- Hormonal Antineoplastic Agents
- Hormonal Antineoplastics
- Antineoplastic Hormonal Drugs
- Drugs, Antineoplastic Hormonal
- Hormonal Drugs, Antineoplastic
- Hormonal Antineoplastic Drugs
- Antineoplastics, Hormonal
- Antineoplastic Hormonal Agents
- Agents, Antineoplastic Hormonal
- Antineoplastic Drugs, Hormonal
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".
This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in Harvard Catalyst Profiles by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publication.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.
New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer. Curr Treat Options Oncol. 2023 Jun; 24(6):594-610.
Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLoS One. 2023; 18(2):e0281508.
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023 Mar 01; 41(7):1376-1382.
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 Mar 01; 41(7):1370-1375.
Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Feb; 197(3):547-558.
Understanding pain related to adjuvant endocrine therapy after breast cancer: A qualitative report. Eur J Cancer Care (Engl). 2022 Nov; 31(6):e13723.
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer. BMC Cancer. 2022 Aug 01; 22(1):837.
Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer. JAMA Netw Open. 2022 08 01; 5(8):e2225345.
Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study. Clin Cancer Res. 2022 05 02; 28(9):1871-1880.
Hormone Treatment of Prostate Cancer:: Evidence for Usage and Safety. Urol Clin North Am. 2022 May; 49(2):309-321.